QT-prolongation in Psychiatric Hospitals

QT-prolongation Clinical Trial

Official title:
QT-prolongation in Psychiatric Hospitals

Status Completed

Clinical Trial Summary

Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug. An ECG is taken before the administration of the new drug and a week after starting the new drug to investigate the change in duration of the QTc-interval. Risk factors for developing QT-prolongation and blood concentrations of potassium and creatinine are documented.

Clinical Trial Description

n/a

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02043925
Study type	Observational
Source	Katholieke Universiteit Leuven
Contact
Status	Completed
Phase	N/A
Start date	October 2010
Completion date	March 2015

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02043912` - Drug Interactions With Risk of QT-prolongation in a General Hospital	N/A
	Completed	`NCT02068170` - Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital	N/A